Pegaspargase administration and tolerability in patients aged 55 years or older with acute lymphoblastic leukemia treated with the LAL1913 program. A subanalysis of the Campus ALL group

Abstract The adoption of pediatric-inspired regimens for the treatment of Ph-negative acute lymphoblastic leukemia (ALL) in adults has improved prognosis. However, the feasibility of these intensive regimens in older patients is limited, due to the increased incidence of therapy-related side effects...

詳細記述

書誌詳細

主要な著者:	Davide Lazzarotto, Anna Maria Testi, Matteo Fanin, Federico Mosna, Sabina Chiaretti, Cristina Papayannidis, Antonio Curti, Matteo Piccini, Nicola Fracchiolla, Monica Fumagalli, Patrizia Zappasodi, Silvia Imbergamo, Paola Minetto, Fabio Guolo, Federico Lussana, Marco Cerrano, Fabio Forghieri, Matteo Leoncin, Matteo Olivi, Monia Lunghi, Silvia Trappolini, Carla Mazzone, Marzia Defina, Lara Aprile, Crescenza Pasciolla, Maria Ciccone, Endri Mauro, Antonino Mulè, Francesco Grimaldi, Benedetta Cambò, Lidia Santoro, Mario Delia, Valentina Mancini, Alessandro Cignetti, Renato Fanin, Massimiliano Bonifacio, Michelina Dargenio, Felicetto Ferrara, Giovanni Pizzolo, Robin Foà, Anna Candoni
フォーマット:	Artigo
言語:	Inglês
出版事項:	Springer 2025-08-01
シリーズ:	Annals of Hematology
主題:	Acute lymphoblastic leukemia Older patients Pegaspargase Real-life study
オンライン･アクセス:	https://doi.org/10.1007/s00277-025-06550-4
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!